AG真人官方

On 11 July 2025, I-MAB (Nasdaq: IMAB) submitted a Form 6-K to notify investors that it has amended its 15 May 2025 prospectus covering the offer and sale of up to US$21 million in American Depositary Shares (ADSs). Each block of ten ADSs represents twenty-three ordinary shares with a par value of US$0.0001. The prospectus is part of the company鈥檚 shelf Registration Statement on Form F-3 (File No. 333-286954).
The filing attaches a Cayman Islands legal opinion from Harney Westwood & Riegels (Exhibit 5.1) together with the corresponding consent (Exhibit 23.1), confirming the validity of the ADSs and underlying ordinary shares. The 6-K states that the information and exhibits are incorporated by reference into the existing Form F-3 and several Form S-8 registration statements covering share-based compensation plans.
No operating or financial results are disclosed. The amendment maintains regulatory compliance and keeps the shelf registration effective, giving I-MAB flexibility to raise up to US$21 million when market conditions permit. While this improves liquidity options, it may also lead to equity dilution for current shareholders if the full amount is issued.

Mineralys Therapeutics, Inc. (MLYS) has filed a Form 144 indicating a planned sale of 15,884 common shares through broker Merrill Lynch. Based on the stated aggregate market value, the transaction is valued at approximately $230,430. The shares were acquired on 07/10/2025 via the vesting of a restricted stock unit award granted under the company鈥檚 equity-compensation plan and are expected to be sold on or after 07/11/2025 on the NASDAQ.

The filing shows 65,175,287 shares outstanding; the proposed sale therefore represents roughly 0.02 % of total shares. No other sales by the filer have occurred in the past three months, and no material adverse information was asserted in the certification section.

VirnetX Holding Corp. (VHC) filed a Form 4 reporting an automatic, non-discretionary insider transaction by Chief Scientist Robert D. Short III on 07/07/2025. The company withheld 50 common shares (Transaction Code F) at a price of $12.34 to satisfy payroll and income-tax obligations linked to previously granted restricted stock awards. The explanatory note confirms the transaction is strictly for tax settlement and does not involve an open-market sale.

Post-transaction ownership stands at 31,848 direct shares and 11,278 indirect shares held through The Short Revocable Living Trust, leaving Short鈥檚 overall economic exposure essentially unchanged. No derivative securities were exercised, acquired, or disposed of, and no other insider activity was disclosed. Given the immaterial size (鈮�0.1 % of Short鈥檚 total holdings) and its administrative nature, the filing carries limited investment significance and signals no shift in insider sentiment toward VirnetX.

I-MAB has announced positive Phase 1b dose escalation data for their drug candidate Givastomig in combination with immunochemotherapy for first-line treatment of gastric cancers. The results were presented at the ESMO GI 2025 conference.

This Form 6-K, filed by the Maryland-based biopharmaceutical company, includes an exhibit (99.1) containing the press release detailing the clinical trial outcomes. The filing was signed by Joseph Skelton, the company's Chief Financial Officer.

The filing indicates that I-MAB continues to file annual reports under Form 20-F as a foreign private issuer. This development represents a significant milestone in I-MAB's oncology pipeline, particularly in the gastric cancer treatment landscape.